Glenmark Pharmaceuticals (NSE:GLENMARK, BOM:532296) said its U.S. arm has launched Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL) single-dose vials, according to a Friday filing on Indian bourses.
The product is a generic version of Vimpat Injection, 200 mg/20 mL, marketed by UCB, the filing said.
Lacosamide injection is indicated for the treatment of partial-onset seizures and primary generalized tonic-clonic seizures.
Shares of the company fell nearly 1% in recent trade.